Short answer
CRISPR Therapeutics AG (CRSP) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Andrew J. Silver appointed CFO, principal financial officer and principal accounting officer effective October 19, 2026.
CRISPR Therapeutics AG 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Andrew J. Silver appointed CFO, principal financial officer and principal accounting officer effective October 19, 2026
- Internal promotion strengthens continuity, leveraging Silver’s finance, accounting, treasury and reporting experience since joining in 2018
- Compensation: $515,000 salary, 45% target bonus and 25,000 RSUs vesting fully after two years
- Former CFO Raju Prasad resigned for external opportunities, with no reported disagreements over operations, accounting or controls
- Prasad expected to remain employed through a date on or before November 30, 2026, supporting transition continuity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CRISPR Therapeutics AG 8-K filings
Get the next CRSP 8-K as it lands
Follow CRSP for push alerts, or ask the research agent what this filing means.